2004062212

12 10CT 2004

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 November 2003 (20.11.2003)

PCT

(10) International Publication Number
WO 03/094915 A1

(51) International Patent Classification[7]: A61K 31/41, A61P 7/02

(21) International Application Number: PCT/EP03/04997

(22) International Filing Date: 13 May 2003 (13.05.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/380,373 14 May 2002 (14.05.2002) US
60/395,014 11 July 2002 (11.07.2002) US

(71) Applicant *(for all designated States except AT, US)*: NOVARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basle (CH).

(71) Applicant *(for AT only)*: NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, A-1230 Vien (AT).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: MALININ, Alex [RU/US]; 9 Windy Cliff Place, Apt. H., Cockeysville, MD 21030 (US). SEREBRUANY, Victor, L. [US/US]; 9101 East Stayman Drive, Ellicott City, MD 21042 (US). WEBB, Randy, Lee [US/US]; 17 Honeyman Drive, Flemington, NJ 08822 (US).

(74) Agent: GROS, Florent; Novartis AG, Corporate Intellectual Property, Patent & Trademark Department, CH-4002 Basel (CH).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

162162

ACTION

WO 03/094915 A1

(54) Title: USE OF VALSARTAN OT ITS METABOLITE TO INHIBIT PLATELET AGGREGATION

(57) Abstract: The invention relates to a method of inhibiting platelet aggregation comprising administering a therapeutically effective amount of an ARB or its metabolite, especially Valsartan or its metabolite valeryl 4-hydroxy valsartan. Conditions to be treated by inhibition of platelet aggregation include acute myocardial infarction, ischemic stroke, angina pectoris, acute coronary syndromes, TIA (transient ischemic attacks, or acute cerebrovascular syndromes), heart failure, chest pain of ischemic etiology, syndrome X, thromboembolism, pulmonary hypertension, diabetes mellitus, peripheral vascular disease, deep vein thrombosis, arterial thrombosis of any vessel, catheter thrombotic occlusion or reocclusion.